Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

This trial is testing whether immunotherapy with cemiplimab (an immune checkpoint inhibitor) given after aggressive local treatments (surgery and/or radiation) can prevent cancer recurrence in patients with non-small cell lung cancer (NSCLC) that was limited to a small number of sites when first diagnosed (called oligometastatic disease). **You may be eligible if...** - You are 18 or older with confirmed NSCLC - At diagnosis, your cancer had spread to a maximum of 5 spots in no more than 3 organs (oligometastatic) - Your cancer remained oligometastatic at the time of study entry - You are in good overall health (ECOG/WHO 0–1) - Your blood counts and organ function are acceptable **You may NOT be eligible if...** - Your lung cancer has small-cell features - Your cancer has spread beyond the oligometastatic threshold - You are pregnant or breastfeeding - You have a history of severe autoimmune disease - You have active brain metastases not adequately treated Talk to your doctor to see if this trial is right for you.